LC-MS based simultaneous profiling of adrenal hormones of steroids, catecholamines, and metanephrines
Journal of Lipid Research · 2023
DOI: 10.1016/j.jlr.2023.100453 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Lipid Research, 2023. Verfasst von Jongsung Noh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology, Seoul, Korea; Department of Chemistry, Kyonggi University, S…. Hauptthemen laut MEDLINE: Cushing Syndrome, Adrenal Gland Neoplasms, Pheochromocytoma, Hyperaldosteronism. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIEHS NIH HHS, Korea Ministry of Health and Welfare.
Abstract (Originalsprache)
Metabolic changes in adrenocortical steroids and medullary catecholamines characterize adrenal tumors, but they are measured using different analytical protocols. To increase bioanalytical validity while maintaining sample homogeneity, LC-MS-based profiling of 29 cortical steroids and 6 medullary amines, including catecholamines and metanephrines, in a single run was developed. Alkyloxycarbonylation with isobutyl chloroformate was employed together with our comprehensive steroid assay, and all adrenal hormones were separated on a reversed-phase C18 column (50 × 2.1 mm, 1.9 μm) at a flow rate of 0.3 ml/min. The lower limits of quantification for all analytes ranged from 0.1 to 2.0 ng/ml, with extraction recoveries of 58.5%-109.5%, while the imprecision and accuracy were 1.6%-14.8% and 89.2%-114.9%, respectively. The validated LC-MS assay was applied to serum samples obtained from 60 patients with adrenal Cushing syndrome, primary aldosteronism, and pheochromocytoma/paraganglioma (PPGL). In addition to the characteristic metabolic changes in glucocorticoids, mineralocorticoids, catecholamines, and metanephrine, the molecular ratios of dehydroepiandrosterone sulfate and 20α-dihydrocortisol indicated Cushing syndrome and primary aldosteronism (P < 0.01 for all compounds), respectively. Moreover, the interactive molecular ratios of 11-deoxycortisol with normetanephrine, metanephrine, norepinephrine, and epinephrine (P < 0.01 all compounds) were proposed to characterize the metabolic features of PPGL. Novel LC-MS-based quantitative profiling of steroids, catecholamines, and metanephrines in human serum was successfully established and characterized metabolic features of individual adrenal tumors that could be used for clinical purposes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology, Seoul, Korea; Department of Chemistry, Kyonggi University, Suwon, Korea.
- Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology, Seoul, Korea.
- Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Korea.
- Department of Chemistry, Kyonggi University, Suwon, Korea.
- Center for Advanced Biomolecular Recognition, Korea Institute of Science and Technology, Seoul, Korea. Electronic address: mh_choi@kist.re.kr.
Förderung
- NIEHS NIH HHS
- Korea Ministry of Health and Welfare
Zitieren
APA
Noh, J., Lee, C., Kim, J. H., Myung, S. W., & Choi, M. H. (2023). LC-MS based simultaneous profiling of adrenal hormones of steroids, catecholamines, and metanephrines. Journal of Lipid Research. https://doi.org/10.1016/j.jlr.2023.100453
Vancouver
Noh J, Lee C, Kim JH, Myung SW, Choi MH. LC-MS based simultaneous profiling of adrenal hormones of steroids, catecholamines, and metanephrines. Journal of Lipid Research. 2023. doi:10.1016/j.jlr.2023.100453
BibTeX
@article{Noh2023,
author = {Noh, Jongsung and Lee, Chaelin and Kim, Jung Hee and Myung, Seung Woon and Choi, Man Ho},
title = {LC-MS based simultaneous profiling of adrenal hormones of steroids, catecholamines, and metanephrines},
journal = {Journal of Lipid Research},
year = {2023},
doi = {10.1016/j.jlr.2023.100453}
}
EUVIMED